Form 8-K - Current report:
SEC Accession No. 0001437749-25-002610
Filing Date
2025-02-03
Accepted
2025-02-03 16:40:42
Documents
19
Period of Report
2025-01-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20250203_8k.htm   iXBRL 8-K 36559
2 EXHIBIT 10.1 ex_773641.htm EX-10.1 139341
3 EXHIBIT 10.2 ex_773940.htm EX-10.2 139918
4 EXHIBIT 99.1 ex_773941.htm EX-99.1 21066
9 logo01.jpg GRAPHIC 3904
10 logo02.jpg GRAPHIC 9588
  Complete submission text file 0001437749-25-002610.txt   585349

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20250128.xsd EX-101.SCH 3870
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20250128_def.xml EX-101.DEF 13795
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20250128_lab.xml EX-101.LAB 18157
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20250128_pre.xml EX-101.PRE 13827
21 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20250203_8k_htm.xml XML 4834
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 25583174
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)